Short answer
Abbott Laboratories (ABT) filed an 8-K current report with the SEC on November 16, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Change-in-control agreements extended through December 31, 2028 for named executives other than CEO Robert B. Ford.
Abbott Laboratories 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Change-in-control agreements extended through December 31, 2028 for named executives other than CEO Robert B. Ford
- Ford’s change-in-control agreement expires December 31, 2026
- CEO exclusion creates potential transition or retention uncertainty around Abbott’s top executive role
- No departure or succession announcement disclosed in this filing
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Abbott Laboratories 8-K filings
Get the next ABT 8-K as it lands
Follow ABT for push alerts, or ask the research agent what this filing means.